Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis (IPA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02338427|
Recruitment Status : Recruiting
First Posted : January 14, 2015
Last Update Posted : January 11, 2017
Amyloidosis is involved in many rare diseases in relation to the diversity of amyloid proteins involved in the formation of abnormal tissue deposits. There are approximately 30 proteins involved in amylose's constitution. The therapeutic management varies depending on the type of amyloidosis observed.
The application of conventional techniques immunolabeling of amylose does not allow the comprehensive characterization of amylose forms, due to failures of the technic, the false positivity of some results, or lack of frozen tissue available for typing light chain (lambda, kappa).
In this study, the main objective is the comparison of two capacity of amylose characterisation: immunohistochemistry and proteomics analysis.
The purpose of this study is to validate the superiority of proteomic analysis by demonstrating the improvement of the precision, the reduction of technical failure, as well as the correction of erroneous diagnosis, authorizing a more adapted therapeutic management.
|Condition or disease||Intervention/treatment||Phase|
|Amyloidosis||Other: Immunohistochemistry Other: Proteomic analysis||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||130 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis. Multicenter Prospective|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||November 2017|
|Estimated Study Completion Date :||August 2019|
Other: Proteomic analysis
- Identification success of amylose by immunohistochemistry and proteomic analysis [ Time Frame: Inclusion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02338427
|Contact: Lucie AUZANNEAU||02 51 44 63 firstname.lastname@example.org|
|Centre Hospitalier Departemental Vendee||Recruiting|
|La Roche sur Yon, France, 85925|
|Principal Investigator: Hervé MAISONNEUVE|
|CHU de Nantes||Recruiting|
|Nantes, France, 44000|
|Principal Investigator: Philippe MOREAU, Pr|
|Study Director:||Hervé MAISONNEUVE, PH||Centre Hospitalier Départementel Vendée|